MXPA02012793A - Composicion de dilatacion rapida para la retencion gastrica y la liberacion controlada de agentes terapeuticos y formas de dosificacion de la composicion. - Google Patents
Composicion de dilatacion rapida para la retencion gastrica y la liberacion controlada de agentes terapeuticos y formas de dosificacion de la composicion.Info
- Publication number
- MXPA02012793A MXPA02012793A MXPA02012793A MXPA02012793A MXPA02012793A MX PA02012793 A MXPA02012793 A MX PA02012793A MX PA02012793 A MXPA02012793 A MX PA02012793A MX PA02012793 A MXPA02012793 A MX PA02012793A MX PA02012793 A MXPA02012793 A MX PA02012793A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- dosage forms
- controlled release
- therapeutic agents
- forms including
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
Abstract
La presente invencion brinda una composicion farmaceutica de uso en formas de dosificacion para la administracion oral al paciente. La composicion se dilata en contacto con liquidos gastrointestinales y genera la retencion de la forma de dosificacion en el estomago del paciente durante un periodo de tiempo prolongado. La presente invencion ademas provee formas de dosificacion farmaceuticas que contienen un ingrediente activo, y la composicion farmaceutica. Las formas se adaptan a la liberacion in mediata o controlada del ingrediente activo. Las formas de dosificacion se pueden usar ventajosamente en el tratamiento de la enfermedad de Parkinson con levodopa y en el Trastorno de Deficit de Atencion e Hiperactividad con metilfenidato.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21383200P | 2000-06-23 | 2000-06-23 | |
US21711000P | 2000-07-10 | 2000-07-10 | |
US22321200P | 2000-08-04 | 2000-08-04 | |
PCT/US2001/020134 WO2002000213A1 (en) | 2000-06-23 | 2001-06-22 | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA02012793A true MXPA02012793A (es) | 2004-07-30 |
Family
ID=27395915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA02012793A MXPA02012793A (es) | 2000-06-23 | 2001-06-22 | Composicion de dilatacion rapida para la retencion gastrica y la liberacion controlada de agentes terapeuticos y formas de dosificacion de la composicion. |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1305021A4 (es) |
JP (1) | JP2004501190A (es) |
KR (1) | KR20030013460A (es) |
AU (2) | AU2001268722B8 (es) |
CA (1) | CA2412490A1 (es) |
CZ (1) | CZ2003199A3 (es) |
EA (1) | EA200300046A1 (es) |
HU (1) | HUP0301465A3 (es) |
IL (1) | IL153497A0 (es) |
MX (1) | MXPA02012793A (es) |
WO (1) | WO2002000213A1 (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7608640B2 (en) | 1999-03-02 | 2009-10-27 | Jallal Messadek | Glycine betaine and its use |
EP1416914A1 (en) * | 2001-08-16 | 2004-05-12 | The State of Oregon acting by and through The State Board of Higher Education on behalf of Oregon State University | Expandable gastric retention device |
BE1015608A6 (fr) | 2003-07-15 | 2005-06-07 | Messadek Jallal | Traitement des arterites. |
US20030224045A1 (en) * | 2002-05-29 | 2003-12-04 | Chien-Hsuan Han | Combination immediate release sustained release levodopa/carbidopa dosage forms |
US7094427B2 (en) * | 2002-05-29 | 2006-08-22 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
DE602004003577T2 (de) * | 2003-04-17 | 2007-09-20 | Jallal Messadek | Flottierende orale Formulierungen mit kontrollierter Freisetzung von Betain |
US20050113452A1 (en) * | 2003-10-20 | 2005-05-26 | Moshe Flashner-Barak | Composition and dosage form for sustained effect of levodopa |
JP2005132803A (ja) * | 2003-10-31 | 2005-05-26 | Ono Pharmaceut Co Ltd | 胃内滞留固形剤 |
TW200533391A (en) | 2004-03-25 | 2005-10-16 | Sun Pharmaceutical Ind Ltd | Gastric retention drug delivery system |
FR2874325B1 (fr) * | 2004-08-19 | 2006-10-20 | Sanofi Synthelabo | Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine |
WO2006050581A2 (en) | 2004-11-10 | 2006-05-18 | Jallal Messadek | Betaine as agent against arthropod - or mosquito -borne diseases |
WO2006086856A1 (en) | 2005-02-15 | 2006-08-24 | Messadek, Jallal | Combination therapeutic compositions and method of use |
WO2006113978A2 (en) | 2005-04-27 | 2006-11-02 | Jallal Messadek | Insulins combinations |
NL2000281C2 (nl) | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Vaste farmaceutische samenstellingen die pregabaline bevatten. |
AU2007267135B2 (en) * | 2006-05-31 | 2013-03-07 | AbbVie Pharmaceuticals GmbH | Long term 24 hour intestinal administration of levodopa/carbidopa |
EP1872775A1 (en) | 2006-06-29 | 2008-01-02 | Polichem S.A. | Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders |
CL2007002574A1 (es) * | 2006-09-08 | 2008-05-23 | Drug Tech Corp Sa Organizada B | Composicion farmaceutica oral que comprende levodopa en una dosis unitaria de alrededor de 100 hasta alrededor de 500 mg y un excipiente adecuado; y su uso para tratar parkinson. |
WO2008039186A2 (en) * | 2006-09-26 | 2008-04-03 | Plensat, Llc | Method and system for treatment of eating disorders |
WO2008087882A1 (ja) | 2007-01-15 | 2008-07-24 | Kissei Pharmaceutical Co., Ltd. | 胃内滞留型レボドパ徐放性製剤 |
KR20080076382A (ko) * | 2007-02-15 | 2008-08-20 | (주)아모레퍼시픽 | 실로스타졸의 제어방출 제제 및 그 제조방법 |
DE102007026037A1 (de) * | 2007-06-04 | 2008-12-11 | Lts Lohmann Therapie-Systeme Ag | Gastroretentives System mit Alginat-Körper |
JP2010534721A (ja) * | 2007-07-27 | 2010-11-11 | ディポメド,インコーポレイティド | パルス型胃滞留性製剤 |
AU2009267052B2 (en) | 2008-06-30 | 2013-07-11 | Tocagen Inc. | Formulations of 5-fluorocytosine and uses thereof |
MX340249B (es) | 2008-08-15 | 2016-07-01 | Depomed Inc | Composiciones farmacéuticas retentivas gástricas para tratamiento y prevención de transtornos del sistema nervioso central (cns). |
AU2009311877C1 (en) * | 2008-11-07 | 2013-08-15 | Samyang Holdings Corporation | Pharmaceutical composition for release control of methylphenidate |
WO2012093974A1 (en) * | 2011-01-06 | 2012-07-12 | Mahmut Bilgic | Improved bisphosphonate formulations |
CN103385871B (zh) * | 2012-05-07 | 2017-06-23 | 新疆医科大学 | 复方左旋多巴微囊漂浮片 |
EP2858604B1 (en) | 2012-06-07 | 2024-02-21 | Epitomee Medical Ltd | Expanded device |
WO2014174388A1 (en) * | 2013-03-29 | 2014-10-30 | Wockhardt Limited | Modified release pharmaceutical compositions of methylphenidate or salts thereof |
JP6204141B2 (ja) * | 2013-04-22 | 2017-09-27 | テイカ製薬株式会社 | 口腔内速崩壊性固形製剤用組成物 |
WO2014176389A1 (en) * | 2013-04-24 | 2014-10-30 | Temple University - Of The Commonwealth System Of Higher Education | Solid dosage form containing arabinogalactan |
US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
EP3782614A1 (en) | 2013-10-07 | 2021-02-24 | Impax Laboratories, LLC | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
EP3091962B1 (en) | 2013-12-05 | 2022-06-08 | Epitomee Medical Ltd. | Retentive devices and systems for in-situ release of pharmaceutical active agents |
JP2018506590A (ja) * | 2015-02-27 | 2018-03-08 | シンギュレイト・セラピューティクス・リミテッド・ライアビリティ・カンパニーCingulate Therapeutics LLC | トリパルス放出型賦活薬製剤 |
JP6823539B2 (ja) * | 2017-05-26 | 2021-02-03 | 株式会社ファンケル | 胃内滞留性錠剤 |
US10987311B2 (en) | 2017-06-16 | 2021-04-27 | Kashiv Specialty Pharmaceuticals, Llc | Extended release compositions comprising pyridostigmine |
US10588863B2 (en) | 2017-06-16 | 2020-03-17 | Kashiv Biosciences, Llc | Extended release compositions comprising pyridostigmine |
WO2018232413A1 (en) | 2017-06-16 | 2018-12-20 | Kashiv Pharma Llc | Gastroretentive dosage forms for sustained drug delivery |
WO2019246145A1 (en) | 2018-06-18 | 2019-12-26 | Kashiv Biosciences, Llc | Extended release compositions comprising pyridostigmine |
CA3065695C (en) | 2018-06-27 | 2021-06-01 | Kashiv Biosciences, Llc | Self-regulating osmotic gastroretentive drug delivery systems |
JP7044649B2 (ja) * | 2018-06-28 | 2022-03-30 | 株式会社ファンケル | 胃内浮遊錠剤 |
CA3139217A1 (en) | 2019-05-14 | 2020-11-19 | Clexio Biosciences Ltd. | Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease |
JP2023516370A (ja) * | 2020-03-02 | 2023-04-19 | クラフト ヘルス プライベート リミテッド | 持続的薬物放出のための経口剤形 |
US11571402B2 (en) * | 2021-02-17 | 2023-02-07 | Springworks Therapeutics, Inc. | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
WO2022195476A1 (en) | 2021-03-15 | 2022-09-22 | Clexio Biosciences Ltd. | Gastroretentive devices for assessment of intragastric conditions |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
US4167558A (en) * | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
US4434153A (en) * | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
IT1282650B1 (it) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
JP2001510788A (ja) * | 1997-07-23 | 2001-08-07 | ペリオ プロダクツ リミテッド | 薬学的薬剤を薬学的に口腔内に制御放出するためのタンニン酸ポリマー組成物 |
-
2001
- 2001-06-22 AU AU2001268722A patent/AU2001268722B8/en not_active Ceased
- 2001-06-22 WO PCT/US2001/020134 patent/WO2002000213A1/en active IP Right Grant
- 2001-06-22 EA EA200300046A patent/EA200300046A1/ru unknown
- 2001-06-22 EP EP01946709A patent/EP1305021A4/en not_active Withdrawn
- 2001-06-22 IL IL15349701A patent/IL153497A0/xx unknown
- 2001-06-22 JP JP2002504995A patent/JP2004501190A/ja active Pending
- 2001-06-22 HU HU0301465A patent/HUP0301465A3/hu unknown
- 2001-06-22 CZ CZ2003199A patent/CZ2003199A3/cs unknown
- 2001-06-22 AU AU6872201A patent/AU6872201A/xx active Pending
- 2001-06-22 KR KR1020027017538A patent/KR20030013460A/ko not_active Application Discontinuation
- 2001-06-22 MX MXPA02012793A patent/MXPA02012793A/es not_active Application Discontinuation
- 2001-06-22 CA CA002412490A patent/CA2412490A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CZ2003199A3 (cs) | 2003-12-17 |
EA200300046A1 (ru) | 2003-10-30 |
AU2001268722B8 (en) | 2005-09-29 |
EP1305021A4 (en) | 2009-09-23 |
HUP0301465A3 (en) | 2006-07-28 |
WO2002000213A1 (en) | 2002-01-03 |
EP1305021A1 (en) | 2003-05-02 |
AU6872201A (en) | 2002-01-08 |
CA2412490A1 (en) | 2002-01-03 |
AU2001268722B2 (en) | 2005-08-11 |
IL153497A0 (en) | 2003-07-06 |
HUP0301465A2 (hu) | 2004-05-28 |
KR20030013460A (ko) | 2003-02-14 |
JP2004501190A (ja) | 2004-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA02012793A (es) | Composicion de dilatacion rapida para la retencion gastrica y la liberacion controlada de agentes terapeuticos y formas de dosificacion de la composicion. | |
MXPA02012792A (es) | Composicion y forma de de dosificacion para liberacion gastrica retardada de alendronato y/u otros bis-fosfonatos. | |
NO993520L (no) | Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon | |
IL174562A0 (en) | Oros push-stick for controlled delivery of active agent | |
WO2004112711A3 (en) | Oral extended-release composition | |
GB2431346C (en) | A combination composition comprising paracetamol and ibuprofen | |
HUP0203733A2 (en) | Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy | |
HUP0102489A2 (hu) | Biokémiai anyagok alkalmazása emberi test szerveiben található simaizomsejtek összehúzódása okozta egészségi állapotok megelőzésére és kezelésére alkalmas készítményekben | |
HUP0004300A2 (hu) | (S)-N-Etil-3-[1-(dimetil-amino)-etil]-N-metil-fenil-karbamátot és antioxidánst tartalmazó gyógyszerkészítmény | |
PT1471892E (pt) | Sistema terapêutico transdérmico para a doença de parkinson induzindo níveis elevados de rotigotina no plasma | |
IS7006A (is) | Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd | |
HK1060691A1 (en) | Ion-strength independent sustained release pharmaceutical formulation | |
MY137570A (en) | Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease | |
BR0108261A (pt) | Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono | |
DE50000864D1 (de) | Verwendung von desoxypeganin zur behandlung von drogenabhängigkeit | |
HUP0301408A2 (hu) | Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására | |
DE50010973D1 (de) | Pharmazeutische zusammensetzung, enthaltend desoxypeganin zur behandlung des alkoholismus | |
WO2005060939A3 (en) | Controlled-release pharmaceutical formulation | |
PT1572686E (pt) | Derivados de amida do ácido antranílico e suas utilizações farmacêuticas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |